In this article, we will list the 5 Best Small Cap Stocks to Buy for 10x Potential. Please visit 15 Best Small Cap Stocks to Buy for 10x Potential if you would like to see the extended list and the methodology behind it.
5. Surgery Partners, Inc. (NASDAQ:SGRY)
Number of Hedge Fund Holders: 35
Surgery Partners, Inc. (NASDAQ:SGRY) is one of the best small cap stocks to buy for 10x potential. Jefferies lifted the price target on Surgery Partners, Inc. (NASDAQ:SGRY) to $17 from $15 on May 7, maintaining a Buy rating on the shares and stating that the company delivered good fiscal Q1 results, especially given the weather-related headwinds that affected most health-care services providers. It added that payor mix issues that emerged last quarter moderated in Q1, and should gradually improve over the course of the year.
The rating update came after Surgery Partners, Inc. (NASDAQ:SGRY) reported its fiscal Q1 2026 financial results on May 5, reporting that revenue grew 4.5% year-over-year, with same-facility revenue growing 4.4% and same-facility cases rising 0.6%. Net loss attributable to the company was $35.9 million for fiscal Q1 2026, while adjusted EBITDA was $102.3 million. Surgery Partners, Inc. (NASDAQ:SGRY) also provided 2026 guidance, reaffirming full-year 2026 revenue guidance to be in the range of $3.35 billion to $3.45 billion, and adjusted EBITDA of at least $530 million.
Surgery Partners, Inc. (NASDAQ:SGRY) is a healthcare services holding company that provides solutions for surgical and related ancillary care in support of physicians and patients. The company’s operations are divided into the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services.
4. BlackLine, Inc. (NASDAQ:BL)
Number of Hedge Fund Holders: 37
BlackLine, Inc. (NASDAQ:BL) is one of the best small cap stocks to buy for 10x potential. Piper Sandler lifted the price target on BlackLine, Inc. (NASDAQ:BL) to $37 from $35 on May 7, maintaining a Neutral rating on the shares. The firm stated that steady progress on the transition story continued in fiscal Q1, with platform pricing attach continuing to progress well and expanding to 13% of total eligible ARR from just 4% two quarters ago. It was encouraged by management reasserting line of sight to exceeding 50% non-seat based pricing mix exiting 2026. However, Piper added that although it finds the progress and results encouraging, the firm is remaining on the sidelines given the ongoing transition and overall enterprise budget priority concerns in a backdrop where the significant AI investment cycle unfolds across the enterprise.
BlackLine, Inc. (NASDAQ:BL) also received a rating update from Truist the same day. The firm cut the price target on the stock to $32 from $50 and reiterated a Hold rating on the shares.
BlackLine, Inc. (NASDAQ:BL) provides a cloud-based software platform involved in controlling and automating financial close and accounting processes. The company’s operations are divided into the United States and International geographical segments.
3. ADMA Biologics, Inc. (NASDAQ:ADMA)
Number of Hedge Fund Holders: 38
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the best small cap stocks to buy for 10x potential. On May 7, Mizuho lowered the price target on ADMA Biologics, Inc. (NASDAQ:ADMA) to $20 from $24 while maintaining an Outperform rating on the shares. The stock also received a rating update from Canaccord the same day, with the firm cutting the price target on the stock to $18 from $21 while maintaining a Buy rating on the shares. It stated that fiscal Q1 2026 was a reset quarter for ADMA Biologics, Inc. (NASDAQ:ADMA), with results falling short and guidance lowered primarily because of pressure on Bivigam within the standard IG market. It also stated that the key product and value driver, Asceniv, held up pretty well in the quarter.
In its financial results for fiscal Q1 2026 released on May 6, ADMA Biologics, Inc. (NASDAQ:ADMA) reported total revenue of $114.5 million, flat year-over-year, with ASCENIV revenue growing 28% year-over-year and BIVIGAM revenue dropping 54% year-over-year.
ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops speciality plasma-derived biologics. It conducts operations through the following business segments: ADMA BioManufacturing and Plasma Collection Center.
2. ProPetro Holding Corp. (NYSE:PUMP)
Number of Hedge Fund Holders: 44
ProPetro Holding Corp. (NYSE:PUMP) is one of the best small cap stocks to buy for 10x potential. On May 7, Barclays upgraded ProPetro Holding Corp. (NYSE:PUMP) to Overweight from Equal Weight. The rating update came after the company reported its fiscal Q1 2026 financial results, with total revenue coming up to $271 million for the quarter, down 7% as compared to $290 million for the previous quarter. Net loss was $4 million ($0.03 loss per diluted share) as compared to a net income of $1 million in the prior quarter ($0.01 income per diluted share).
The company further reported adjusted EBITDA of $36 million, which was 13% of revenue and decreased 29% as compared to the previous quarter. Capital expenditures paid were $43 million, while capital expenditures incurred were $85 million.
ProPetro Holding Corp. (NYSE:PUMP) also announced that it entered into a strategic framework agreement with Caterpillar Inc., securing access to up to 2.1 additional gigawatts of power generation capacity over the next five years. The agreement bolsters long-term supply visibility while supporting PROPWR’s continued growth, with the company now positioned to have approximately 2.6 gigawatts of power generation capacity delivered by year-end 2031.
ProPetro Holding Corp. (NYSE:PUMP) is an oilfield services company that provides hydraulic fracturing and other complementary services. Its operations are divided into the following segments: Hydraulic Fracturing, Wireline, Cementing, and Power Generation.
1. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Number of Hedge Fund Holders: 53
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the best small cap stocks to buy for 10x potential. On May 4, Stifel lifted the price target on Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to $46 from $45, reaffirming a Buy rating on the shares. It told investors that although modest consensus misses on Revuforj and Niktimvo sales are weighing on the shares, the firm remains “incrementally” more positive and confident in the trajectory of Revuforj.
The rating update came after Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its fiscal Q1 2026 results, reporting a total revenue of $64.9 million for the quarter, reflecting a 224% year-over-year increase. Revuforj® net revenue was $48.9 million, showing leadership in menin inhibition and increasing uptake in R/R NPM1m AML. In addition, Niktimvo™ net revenue reached $55.1 million in the quarter, resulting in Syndax collaboration revenue of $15.9 million. The company also reported that it expects new revumenib real-world, frontline, and post-HSCT maintenance data in fiscal Q2 2026, along with topline data anticipated in fiscal Q4 2026 from Phase 2 trials of axatilimab in IPF and newly diagnosed chronic GVHD.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is involved in the development of cancer therapies, which its products including SyndAccess, Revuforj, Niktimvo, and IncyteCARES.
While we acknowledge the potential of SNDX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNDX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
